buprenorphine hydrochloride and naloxone hydrochloride dihydrate
Generic: buprenorphine hydrochloride and naloxone hydrochloride dihydrate
Labeler: major pharmaceuticalsDrug Facts
Product Profile
Brand Name
buprenorphine hydrochloride and naloxone hydrochloride dihydrate
Generic Name
buprenorphine hydrochloride and naloxone hydrochloride dihydrate
Labeler
major pharmaceuticals
Dosage Form
TABLET
Routes
Active Ingredients
buprenorphine hydrochloride 2 mg/1, naloxone hydrochloride dihydrate .5 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
0904-7009
Product ID
0904-7009_4c41f56b-78b1-4256-b9fc-f7b9b8961fe5
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
ANDA
Application Number
ANDA203326
DEA Schedule
ciii
Listing Expiration
2027-12-31
Marketing Start
2014-06-27
Pharmacologic Class
Classes
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
09047009
Hyphenated Format
0904-7009
Supplemental Identifiers
RxCUI
UNII
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
buprenorphine hydrochloride and naloxone hydrochloride dihydrate (source: ndc)
Generic Name
buprenorphine hydrochloride and naloxone hydrochloride dihydrate (source: ndc)
Application Number
ANDA203326 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 2 mg/1
- .5 mg/1
Packaging
- 50 BLISTER PACK in 1 CARTON (0904-7009-06) / 1 TABLET in 1 BLISTER PACK
Packages (1)
Ingredients (2)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["SUBLINGUAL"], "spl_id": "4c41f56b-78b1-4256-b9fc-f7b9b8961fe5", "openfda": {"unii": ["5Q187997EE", "56W8MW3EN1"], "rxcui": ["351266", "351267"], "spl_set_id": ["c5fbec69-e7de-44a8-b9fa-0378ae61a9fe"], "manufacturer_name": ["Major Pharmaceuticals"]}, "finished": true, "packaging": [{"sample": false, "description": "50 BLISTER PACK in 1 CARTON (0904-7009-06) / 1 TABLET in 1 BLISTER PACK", "package_ndc": "0904-7009-06", "marketing_start_date": "20140627"}], "brand_name": "buprenorphine hydrochloride and naloxone hydrochloride dihydrate", "product_id": "0904-7009_4c41f56b-78b1-4256-b9fc-f7b9b8961fe5", "dosage_form": "TABLET", "pharm_class": ["Opioid Antagonist [EPC]", "Opioid Antagonists [MoA]", "Partial Opioid Agonist [EPC]", "Partial Opioid Agonists [MoA]"], "product_ndc": "0904-7009", "dea_schedule": "CIII", "generic_name": "buprenorphine hydrochloride and naloxone hydrochloride dihydrate", "labeler_name": "Major Pharmaceuticals", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "buprenorphine hydrochloride and naloxone hydrochloride dihydrate", "active_ingredients": [{"name": "BUPRENORPHINE HYDROCHLORIDE", "strength": "2 mg/1"}, {"name": "NALOXONE HYDROCHLORIDE DIHYDRATE", "strength": ".5 mg/1"}], "application_number": "ANDA203326", "marketing_category": "ANDA", "marketing_start_date": "20140627", "listing_expiration_date": "20271231"}